Pancreatic Cancer Research

ResearcherHerlev HospitalActive in the last 2 years

Astrid Zedlitz Johansen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4948-6799; OpenAlex author ID A5030632860, A5110966859. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 5 papers · 2024: 1 paper · 2025: 2 papers

Papers 18

  1. Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2025.116095↗
  2. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  3. Human P2X7 receptor variants Gly150Arg and Arg276His polymorphisms have differential effects on risk association and cellular functions in pancreatic cancer. Co-author DOI 10.1186/s12935-024-03339-9↗
  4. Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Co-author DOI 10.1002/cam4.5240↗
  5. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherap… Co-author DOI 10.3389/fimmu.2023.1228907↗
  6. High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. First author DOI 10.3389/fmolb.2023.1158058↗
  7. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1211292↗
  8. Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15030897↗
  9. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers14030819↗
  10. Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Co-author DOI 10.3390/cancers14133250↗
  11. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenoc… Co-author DOI 10.1002/ijc.33551↗
  12. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ejca.2020.10.038↗
  13. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival i… Co-author DOI 10.1016/j.ejca.2021.09.009↗
  14. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  15. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. Co-author DOI 10.3390/cancers13184599↗
  16. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.32751↗
  17. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. Co-author DOI 10.1111/ecc.13219↗
  18. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. First author DOI 10.1158/1055-9965.epi-19-0672↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia Sidenius Johansen · 16 shared papers, 2020–2025 · strength 2.26
  2. Inna Markovna Chen · 15 shared papers, 2020–2025 · strength 2.07
  3. Carsten Palnæs Hansen · 11 shared papers, 2020–2025 · strength 1.53
  4. Per Pfeiffer · 7 shared papers, 2020–2025 · strength 0.95
  5. Louise S. Rasmussen · 5 shared papers, 2020–2025 · strength 0.59
  6. M.A. Karsdal · 4 shared papers, 2020–2023 · strength 0.54
  7. Nicholas Willumsen · 4 shared papers, 2020–2023 · strength 0.54
  8. Dorte Lisbet Nielsen · 3 shared papers, 2022–2023 · strength 0.51
  9. Neel Ingemann Nissen · 3 shared papers, 2021–2023 · strength 0.45
  10. Jon Kroll Bjerregaard · 4 shared papers, 2020–2021 · strength 0.40
  11. Lars Henrik Jensen · 2 shared papers, 2023–2025 · strength 0.37
  12. Benjamin Emil Stubbe · 2 shared papers, 2023–2025 · strength 0.36
  13. Stine Dam Henriksen · 2 shared papers, 2023–2025 · strength 0.36
  14. Ole Thorlacius‐Ussing · 2 shared papers, 2023–2025 · strength 0.36
  15. Sidsel C. Lindgaard · 2 shared papers, 2022–2023 · strength 0.33
  16. Lars Nannestad Jørgensen · 2 shared papers, 2021–2023 · strength 0.28
  17. Hadi M. H. Diab · 2 shared papers, 2021–2023 · strength 0.28
  18. I.M. Chen · 1 shared paper, 2025 · strength 0.26
  19. Dan Calatayud · 1 shared paper, 2025 · strength 0.26
  20. Gunilla Høyer‐Hansen · 1 shared paper, 2025 · strength 0.26
  21. Rikke Løvendahl Eefsen · 1 shared paper, 2025 · strength 0.26
  22. Sture Falkmer · 2 shared papers, 2021 · strength 0.21
  23. Ganga Deshar · 1 shared paper, 2024 · strength 0.20
  24. Ivana Novak · 1 shared paper, 2024 · strength 0.20
  25. Lara Magni · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.